A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
ICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are
pulsed with six synthetic peptides that were derived from tumour associated antigens (TAA)
present on glioblastoma tumour cells. This is a Phase 3 study to evaluate ICT-107 in patients
with newly diagnosed glioblastoma. Subjects will be randomized to receive standard of care
chemoradiation (temozolomide (TMZ) with either ICT-107 or a blinded control. Reinfusion with
the pulsed dendritic cells should stimulate cytotoxic T cells to specifically target
glioblastoma tumour cells.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society